Attovia reports ATTO-1310 pruritus proof of concept, plans Phase 2 for 2027

Attovia Therapeutics reported second quarter 2026 results and a pipeline update on September 2, 2026. The company said it finished enrolling and dosing patients in a double-blind, placebo-controlled Phase 1b study covering chronic pruritus and high-itch atopic dermatitis.¹ Preliminary findings showed that a single dose of ATTO-1310 led to fast, deep relief from itching in both patient groups, and patients with high-itch atopic dermatitis also showed consistent control of skin lesions, which the company said served as clinical proof of concept for the drug and its ATTOBODY platform.¹ Full Phase 1b results are expected in the fourth quarter of 2026.¹

On the regulatory side, Attovia said it submitted the Phase 2 protocol for chronic pruritus of unknown origin to the FDA after incorporating agency feedback on trial design and endpoints, with that study set to start in the first half of 2027.¹ A separate global Phase 2 trial in high-itch atopic dermatitis is also planned to begin in the first half of 2027.¹ In China, the company said it received IND clearance in under 30 working days through the NMPA's expedited pathway for a Phase 1b trial in cholestatic pruritus linked to primary biliary cholangitis or primary sclerosing cholangitis.¹

For its earlier-stage programs, Attovia said IND-enabling work for ATTO-2306 is ongoing, with Phase 1 initiation expected in the first half of 2027,¹ and IND-enabling work for ATTO-1091 is also underway, with its Phase 1 start likewise expected in the first half of 2027.¹

On finances, the company reported cash, cash equivalents and marketable securities of $115.1 million as of June 30, 2026, down from $152.3 million at the end of 2025.¹ Attovia said including roughly $305.4 million in net proceeds from its August 2026 IPO, its cash position should fund operations into 2030.¹